Modeling phenotypes of malignant gliomas

被引:15
|
作者
Sampetrean, Oltea [1 ]
Saya, Hideyuki [1 ]
机构
[1] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Keio, Japan
关键词
experimental model; genetically engineered mouse model; glioma cell of origin; glioma invasion; malignant glioma; GROWTH-FACTOR RECEPTOR; NEURAL STEM-CELL; MOSAIC ANALYSIS; DOUBLE MARKERS; MOUSE MODELS; BRAIN-TUMORS; GLIOBLASTOMA; ACTIVATION; MIGRATION; INVASION;
D O I
10.1111/cas.13351
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant gliomas are primary tumors of the central nervous system characterized by diffuse infiltration into the brain and a high recurrence rate. Advances in comprehensive genomic studies have provided unprecedented insight into the genetic and molecular heterogeneity of these tumors and refined our understanding of their evolution from low to high grade. However, similar levels of phenotypic characterization are indispensable to understanding the complexity of malignant gliomas. Experimental glioma models have also achieved great progress in recent years. Advances in transgenic technologies and cell culture have allowed the establishment of mouse models that mirror the human disease with increasing fidelity and which support single-cell resolution for phenotypic analyses. Here we review the major types of preclinical glioma models, with an emphasis on how recent developments in experimental modeling have shed new light on two fundamental aspects of glioma phenotype, their cell of origin and their invasive potential.
引用
收藏
页码:6 / 14
页数:9
相关论文
共 50 条
  • [31] Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas
    Estevez-Ordonez, Dagoberto
    Chagoya, Gustavo
    Salehani, Arsalaan
    Atchley, Travis J.
    Laskay, Nicholas M. B.
    Parr, Matthew S.
    Elsayed, Galal A.
    Mahavadi, Anil K.
    Rahm, Sage P.
    Friedman, Gregory K.
    Markert, James M.
    NEUROSURGERY CLINICS OF NORTH AMERICA, 2021, 32 (02) : 265 - 281
  • [32] Progress on molecular biomarkers and classification of malignant gliomas
    Zhang, Chuanbao
    Bao, Zhaoshi
    Zhang, Wei
    Jiang, Tao
    FRONTIERS OF MEDICINE, 2013, 7 (02) : 150 - 156
  • [33] Fluorescein-Guided Surgery for Malignant Gliomas
    Dellaretti, Marcos
    de Melo, Matheus Tavares
    de Lima, Franklin Bernardes Faraj
    Guazzelli, Sofia
    Costa, Bernardo Brant Ribeiro
    Silva Pereira, Pedro de Souza
    Torres, Rodrigo Espindula
    WORLD NEUROSURGERY, 2023, 174 : 62 - 62
  • [34] Blood-based biomarkers for malignant gliomas
    Matthias Holdhoff
    Susannah G. Yovino
    Osei Boadu
    Stuart A. Grossman
    Journal of Neuro-Oncology, 2013, 113 : 345 - 352
  • [35] Genetically Modified Cellular Therapies for Malignant Gliomas
    Kilian, Michael
    Bunse, Theresa
    Wick, Wolfgang
    Platten, Michael
    Bunse, Lukas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [36] Clinical trials of viral therapy for malignant gliomas
    Piccioni, David E.
    Kesari, Santosh
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (11) : 1297 - 1305
  • [37] KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment
    D'Alessandro, Giuseppina
    Grimaldi, Alfonso
    Chece, Giuseppina
    Porzia, Alessandra
    Esposito, Vincenzo
    Santoro, Antonio
    Salvati, Maurizio
    Mainiero, Fabrizio
    Ragozzino, Davide
    Di Angelantonio, Silvia
    Wulff, Heike
    Catalano, Myriam
    Limatola, Cristina
    ONCOTARGET, 2016, 7 (21) : 30781 - 30796
  • [38] Stem Cells as Vectors to Deliver HSV/tk Gene Therapy for Malignant Gliomas
    Rath, Prakash
    Shi, Huidong
    Maruniak, Joel A.
    Litofsky, N. Scott
    Maria, Bernard L.
    Kirk, Mark D.
    CURRENT STEM CELL RESEARCH & THERAPY, 2011, 6 (01) : 44 - 49
  • [39] Blood-based biomarkers for malignant gliomas
    Holdhoff, Matthias
    Yovino, Susannah G.
    Boadu, Osei
    Grossman, Stuart A.
    JOURNAL OF NEURO-ONCOLOGY, 2013, 113 (03) : 345 - 352
  • [40] Origin of Gliomas
    Cahill, Daniel
    Turcan, Sevin
    SEMINARS IN NEUROLOGY, 2018, 38 (01) : 5 - 10